The Pituitary World News Podcast

In today's podcast, we talk to Anne Vaslin Chessex,  Global Program Leader at  Debiopharm International. In this dynamic chat, we explore Debiopharm's innovative three-month formulation of Octreotide for acromegaly, highlighting the science, clinical trials, and patient benefits. Gain insights into drug development, patient-centered approaches, future treatment options, and learn how to participate in the clinical trial. Dr. Vaslin Chessex has a PhD in Neurosciences and currently oversees the global strategy for drug development programs in rare diseases.  This is a fascinating talk about the science and expertise behind long-acting formulations, patient needs in acromegaly, treatment challenges, and the specifics on the clinical trial design, sites, and recruitment.

Today we welcome to our podcasts Dr. Francesca Galbiati who recently joined the California Center for Pituitary Disorders at UCSF, where she cares for patients with pituitary tumors, acromegaly, Cushing's disease, and related hypothalamic conditions. She is originally from northern Italy and the first in her family to attend college, her path into medicine was driven by a love of science, a desire to work with people, and a passion for understanding how the human body works.  We had a delightful, candid discussion about delays in diagnosis , noting that pituitary disease remains underrepresented in medical education and that primary care physicians often miss early signs.  Among other subjects, we talked abut the promise of AI to aid in early diagnosis, and talked about the new emerging therapies and neuroimaging techniques

In today's podcast, Crinetics co-founders Dr. Scott Struthers and Dr. Steve Betz share their views and experiences in drug discovery and development, revealing what it really takes to bring a new medication from concept to patients. We discuss their recently approved drug for acromegaly, Paltusotine (Palsonify™), along with their pipeline plans for Cushing's disease and congenital adrenal hyperplasia (CAH) Atumelnant. Palsonify™ represents the first drug developed and marketed by Crinetics—a significant milestone for the company. This rare, candid look inside a complex industry offers insights you won't want to miss. Drs. Struthers and Betz are both frequent guests on the Pituitary World News podcast.

In the latest episode of the Pituitary World News podcast, Jorge D. Faccinetti sits down with Dr. Markus Johnsson, Senior VP of R&D at Camurus, to explore the fascinating world of FluidCrystal® technology. This innovative approach promises to revolutionize the way we think about drug delivery, providing long-lasting solutions for chronic diseases particularly for people with acromegaly. Markus shares insights into the development process, the importance of patient feedback, and the future of drug delivery systems. The discussion highlights the significance of sustained release medications and the convenience of self-administration for patients.  Click on the link to learn more about  FluidCrystal®.

En el podcast de hoy hablamos con el Dr. Manel Puig Domingo sobre un estudio innovador que él encabezó y que se describe en un artículo reciente publicado en la revista PITUITARY. El artículo plantea la posibilidad de que los algoritmos de IA y el aprendizaje automático podrían proporcionar un enfoque revolucionario para el diagnóstico temprano de esta enfermedad compleja, cuyo diagnóstico actualmente tarda un promedio de 6 a 10 años. El artículo describe un sistema de reconocimiento facial impulsado por IA, AcroFace, que podría detectar la acromegalia mediante el análisis de fotografías faciales. Estos hallazgos preliminares presentan un sistema con un 93% de precisión. Si la investigación avanza y el programa se valida e implementa, promete ahorrar años de enfermedad no detectada. Sin duda prevendrá el desarrollo de complicaciones de condiciones relacionadas, transformará la acromegalia de una enfermedad incapacitante diagnosticada tardíamente a una condición detectada tempranamente y más manejable sin las molestas comorbilidades, y servirá como modelo para otras enfermedades raras con características faciales.